• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

    3/16/23 9:00:55 AM ET
    $CNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNCE alert in real time by email
    15-12G 1 dp190705_1512g.htm FORM 15-12G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number  001-36310

     

    Concert Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

    65 Hayden Avenue, Suite 3000N
    Lexington, Massachusetts 02421
    (781) 860-0045
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, par value $0.001 per share

    Series X1 Preferred Stock, par value $0.001 per share

    Pre-Funded Warrants to Purchase Shares of Common Stock, par value $0.001 per share

    Warrants to Purchase Shares of Series X1 Preferred Stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) ☒        
      Rule 12g-4(a)(2) ☐        
      Rule 12h-3(b)(1)(i) ☒        
      Rule 12h-3(b)(1)(ii) ☐        
      Rule 15d-6 ☐        
      Rule 15d-22(b) ☐        

     

    Approximate number of holders of record as of the certification or notice date: one (1).

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Concert Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    Date: March 16, 2023   CONCERT PHARMACEUTICALS, INC.
             
          By: /s/ Erik Zwicker
          Name: Erik Zwicker
          Title: Secretary

     

     

     

     

     

    Get the next $CNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNCE

    DatePrice TargetRatingAnalyst
    10/5/2021$13.00 → $9.00Buy
    Mizuho
    More analyst ratings

    $CNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 4:45:50 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 2:35:53 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Concert Pharmaceuticals Inc.

      SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/13/23 9:25:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

      CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a

      3/19/21 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

      Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an

      2/15/23 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CNCE
    SEC Filings

    See more
    • SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:51:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:49:56 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:48:59 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

      15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/16/23 9:00:55 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:21 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:15 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

      Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously

      10/5/21 7:29:28 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:37:54 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:13:03 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Financials

    Live finance-specific insights

    See more
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

      11/7/22 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care